Patient-specific stem cell lines derived from human parthenogenetic blastocysts

E. S. Revazova, N. A. Turovets, O. D. Kochetkova, L. B. Kindarova, L. N. Kuzmichev, J. D. Janus, Marina Pryzhkova

Research output: Contribution to journalArticle

Abstract

Parthenogenetic activation of human oocytes may be one way to produce histocompatible cells for cell-based therapy. We report the successful derivation of six pluripotent human embryonic stem cell (hESC) lines from blastocysts of parthenogenetic origin. The parthenogenetic human embryonic stem cells (phESC) demonstrate typical hESC morphology, express appropriate markers, and possess high levels of alkaline phosphatase and telomerase activity. The phESC lines have a normal 46, XX karyotype, except one cell line, and have been cultured from between 21 to 35 passages. The phESC lines form embryoid bodies in suspension culture and teratomas after injection to immunodeficient animals and give differentiated derivatives of all three embryonic germ layers. DNA profiling of all six phESC lines demonstrates that they are MHC matched with the oocyte donors. The study of imprinted genes demonstrated further evidence of the parthenogenetic origin of the phESC lines. Our research has resulted in a protocol for the production of human parthenogenetic embryos and the derivation of stem cell lines from them, which minimizes the presence of animal-derived components, making the derived phESC lines more suitable for potential clinical use.

Original languageEnglish (US)
Pages (from-to)432-449
Number of pages18
JournalCloning and Stem Cells
Volume9
Issue number3
DOIs
StatePublished - Sep 1 2007
Externally publishedYes

Fingerprint

Blastocyst
Stem Cells
Cell Line
Oocytes
Embryoid Bodies
Germ Layers
DNA Fingerprinting
Human Embryonic Stem Cells
Telomerase
Teratoma
Cell- and Tissue-Based Therapy
Karyotype
Alkaline Phosphatase
Suspensions
Embryonic Structures
Tissue Donors
Injections
Research
Genes

ASJC Scopus subject areas

  • Biotechnology
  • Developmental Biology

Cite this

Revazova, E. S., Turovets, N. A., Kochetkova, O. D., Kindarova, L. B., Kuzmichev, L. N., Janus, J. D., & Pryzhkova, M. (2007). Patient-specific stem cell lines derived from human parthenogenetic blastocysts. Cloning and Stem Cells, 9(3), 432-449. https://doi.org/10.1089/clo.2007.0033

Patient-specific stem cell lines derived from human parthenogenetic blastocysts. / Revazova, E. S.; Turovets, N. A.; Kochetkova, O. D.; Kindarova, L. B.; Kuzmichev, L. N.; Janus, J. D.; Pryzhkova, Marina.

In: Cloning and Stem Cells, Vol. 9, No. 3, 01.09.2007, p. 432-449.

Research output: Contribution to journalArticle

Revazova, ES, Turovets, NA, Kochetkova, OD, Kindarova, LB, Kuzmichev, LN, Janus, JD & Pryzhkova, M 2007, 'Patient-specific stem cell lines derived from human parthenogenetic blastocysts', Cloning and Stem Cells, vol. 9, no. 3, pp. 432-449. https://doi.org/10.1089/clo.2007.0033
Revazova ES, Turovets NA, Kochetkova OD, Kindarova LB, Kuzmichev LN, Janus JD et al. Patient-specific stem cell lines derived from human parthenogenetic blastocysts. Cloning and Stem Cells. 2007 Sep 1;9(3):432-449. https://doi.org/10.1089/clo.2007.0033
Revazova, E. S. ; Turovets, N. A. ; Kochetkova, O. D. ; Kindarova, L. B. ; Kuzmichev, L. N. ; Janus, J. D. ; Pryzhkova, Marina. / Patient-specific stem cell lines derived from human parthenogenetic blastocysts. In: Cloning and Stem Cells. 2007 ; Vol. 9, No. 3. pp. 432-449.
@article{1ee2c100fd5943b4a16b3f5a12920048,
title = "Patient-specific stem cell lines derived from human parthenogenetic blastocysts",
abstract = "Parthenogenetic activation of human oocytes may be one way to produce histocompatible cells for cell-based therapy. We report the successful derivation of six pluripotent human embryonic stem cell (hESC) lines from blastocysts of parthenogenetic origin. The parthenogenetic human embryonic stem cells (phESC) demonstrate typical hESC morphology, express appropriate markers, and possess high levels of alkaline phosphatase and telomerase activity. The phESC lines have a normal 46, XX karyotype, except one cell line, and have been cultured from between 21 to 35 passages. The phESC lines form embryoid bodies in suspension culture and teratomas after injection to immunodeficient animals and give differentiated derivatives of all three embryonic germ layers. DNA profiling of all six phESC lines demonstrates that they are MHC matched with the oocyte donors. The study of imprinted genes demonstrated further evidence of the parthenogenetic origin of the phESC lines. Our research has resulted in a protocol for the production of human parthenogenetic embryos and the derivation of stem cell lines from them, which minimizes the presence of animal-derived components, making the derived phESC lines more suitable for potential clinical use.",
author = "Revazova, {E. S.} and Turovets, {N. A.} and Kochetkova, {O. D.} and Kindarova, {L. B.} and Kuzmichev, {L. N.} and Janus, {J. D.} and Marina Pryzhkova",
year = "2007",
month = "9",
day = "1",
doi = "10.1089/clo.2007.0033",
language = "English (US)",
volume = "9",
pages = "432--449",
journal = "Cellular Reprogramming",
issn = "2152-4971",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Patient-specific stem cell lines derived from human parthenogenetic blastocysts

AU - Revazova, E. S.

AU - Turovets, N. A.

AU - Kochetkova, O. D.

AU - Kindarova, L. B.

AU - Kuzmichev, L. N.

AU - Janus, J. D.

AU - Pryzhkova, Marina

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Parthenogenetic activation of human oocytes may be one way to produce histocompatible cells for cell-based therapy. We report the successful derivation of six pluripotent human embryonic stem cell (hESC) lines from blastocysts of parthenogenetic origin. The parthenogenetic human embryonic stem cells (phESC) demonstrate typical hESC morphology, express appropriate markers, and possess high levels of alkaline phosphatase and telomerase activity. The phESC lines have a normal 46, XX karyotype, except one cell line, and have been cultured from between 21 to 35 passages. The phESC lines form embryoid bodies in suspension culture and teratomas after injection to immunodeficient animals and give differentiated derivatives of all three embryonic germ layers. DNA profiling of all six phESC lines demonstrates that they are MHC matched with the oocyte donors. The study of imprinted genes demonstrated further evidence of the parthenogenetic origin of the phESC lines. Our research has resulted in a protocol for the production of human parthenogenetic embryos and the derivation of stem cell lines from them, which minimizes the presence of animal-derived components, making the derived phESC lines more suitable for potential clinical use.

AB - Parthenogenetic activation of human oocytes may be one way to produce histocompatible cells for cell-based therapy. We report the successful derivation of six pluripotent human embryonic stem cell (hESC) lines from blastocysts of parthenogenetic origin. The parthenogenetic human embryonic stem cells (phESC) demonstrate typical hESC morphology, express appropriate markers, and possess high levels of alkaline phosphatase and telomerase activity. The phESC lines have a normal 46, XX karyotype, except one cell line, and have been cultured from between 21 to 35 passages. The phESC lines form embryoid bodies in suspension culture and teratomas after injection to immunodeficient animals and give differentiated derivatives of all three embryonic germ layers. DNA profiling of all six phESC lines demonstrates that they are MHC matched with the oocyte donors. The study of imprinted genes demonstrated further evidence of the parthenogenetic origin of the phESC lines. Our research has resulted in a protocol for the production of human parthenogenetic embryos and the derivation of stem cell lines from them, which minimizes the presence of animal-derived components, making the derived phESC lines more suitable for potential clinical use.

UR - http://www.scopus.com/inward/record.url?scp=39449099453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449099453&partnerID=8YFLogxK

U2 - 10.1089/clo.2007.0033

DO - 10.1089/clo.2007.0033

M3 - Article

VL - 9

SP - 432

EP - 449

JO - Cellular Reprogramming

JF - Cellular Reprogramming

SN - 2152-4971

IS - 3

ER -